Teemu D. Laajala

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Nuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma.

Nuclear PML expression as a prognostic biomarker in localised clear cell renal cell carcinoma.

Journal: BJUI compass
Published: June 18, 2026

Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.

Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.

Journal: BJU international
Published: December 15, 2025

PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers.

PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers.

Journal: European urology oncology
Published: November 26, 2025

Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma.

Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma.

Journal: BJUI compass
Published: January 27, 2025

MRI-Targeted Prostate Biopsy Introduces Grade Inflation and Overtreatment.

MRI-Targeted Prostate Biopsy Introduces Grade Inflation and Overtreatment.

Journal: medRxiv : the preprint server for health sciences
Published: January 23, 2024

ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer.

ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer.

Journal: Frontiers in pharmacology
Published: December 22, 2023

Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma.

Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma.

Journal: Cancer medicine
Published: October 30, 2023

Microbiome-based risk prediction in incident heart failure: a community challenge.

Microbiome-based risk prediction in incident heart failure: a community challenge.

Journal: medRxiv : the preprint server for health sciences
Published: October 24, 2023

A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.

A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.

Journal: Journal of translational medicine
Published: October 24, 2023

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.

Journal: EMBO molecular medicine
Published: September 04, 2023

NPEPPS Is a Druggable Driver of Platinum Resistance.

NPEPPS Is a Druggable Driver of Platinum Resistance.

Journal: Cancer research
Published: July 04, 2023

Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin.

Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin.

Journal: Science translational medicine
Published: May 24, 2023
Showing 1-12 of 54

Last Updated: 09/26/2026